EPISODE · Jun 2, 2025 · 9 MIN
ASCO 2025: Strand Therapeutics Co-Founder & CEO Jake Becraft discusses the clinical data presentation for the company's IL-12, self-replicating mRNA cancer immunotherapy
from BiotechTV - News · host BiotechTV
He explains why IL-12, and how the self-replicating aspect may be giving this more durability over first generation mRNA cancer immunotherapies. He covers the data, and describes how Strand is seeing the abscopal effect in some patients for this intra-tumoral administered product.
Embed this episode
Ready to play
ASCO 2025: Strand Therapeutics Co-Founder & CEO Jake Becraft discusses the clinical data presentation for the company's IL-12, self-replicating mRNA cancer immunotherapy
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.